311 related articles for article (PubMed ID: 35839811)
1. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis.
Bruni L; Serrano B; Roura E; Alemany L; Cowan M; Herrero R; Poljak M; Murillo R; Broutet N; Riley LM; de Sanjose S
Lancet Glob Health; 2022 Aug; 10(8):e1115-e1127. PubMed ID: 35839811
[TBL] [Abstract][Full Text] [Related]
2. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis.
Bruni L; Diaz M; Barrionuevo-Rosas L; Herrero R; Bray F; Bosch FX; de Sanjosé S; Castellsagué X
Lancet Glob Health; 2016 Jul; 4(7):e453-63. PubMed ID: 27340003
[TBL] [Abstract][Full Text] [Related]
3. Cervical cancer screening coverage in the Americas region: a synthetic analysis.
Fernández-Deaza G; Serrano B; Roura E; Castillo JS; Caicedo-Martínez M; Bruni L; Murillo R
Lancet Reg Health Am; 2024 Feb; 30():100689. PubMed ID: 38332935
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Canfell K; Kim JJ; Brisson M; Keane A; Simms KT; Caruana M; Burger EA; Martin D; Nguyen DTN; Bénard É; Sy S; Regan C; Drolet M; Gingras G; Laprise JF; Torode J; Smith MA; Fidarova E; Trapani D; Bray F; Ilbawi A; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):591-603. PubMed ID: 32007142
[TBL] [Abstract][Full Text] [Related]
6. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
[TBL] [Abstract][Full Text] [Related]
7. Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis.
Bruni L; Albero G; Rowley J; Alemany L; Arbyn M; Giuliano AR; Markowitz LE; Broutet N; Taylor M
Lancet Glob Health; 2023 Sep; 11(9):e1345-e1362. PubMed ID: 37591583
[TBL] [Abstract][Full Text] [Related]
8. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
9. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
10. Resources Required for Cervical Cancer Prevention in Low- and Middle-Income Countries.
Campos NG; Sharma M; Clark A; Kim JJ; Resch SC
PLoS One; 2016; 11(10):e0164000. PubMed ID: 27711124
[TBL] [Abstract][Full Text] [Related]
11. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
12. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
13. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
[TBL] [Abstract][Full Text] [Related]
14. Towards the elimination of cervical cancer in low-income and lower-middle-income countries: modelled evaluation of the effectiveness and cost-effectiveness of point-of-care HPV self-collected screening and treatment in Papua New Guinea.
Nguyen DTN; Simms KT; Keane A; Mola G; Bolnga JW; Kuk J; Toliman PJ; Badman SG; Saville M; Kaldor J; Vallely A; Canfell K
BMJ Glob Health; 2022 Mar; 7(3):. PubMed ID: 35241461
[TBL] [Abstract][Full Text] [Related]
15. Acting on the call for cervical cancer elimination: Planning tools for low- and middle- income countries to increase the coverage and effectiveness of screening and treatment.
Herrick T; Thomson KA; Shin M; Gannon S; Tsu V; de Sanjosé S
BMC Health Serv Res; 2022 Oct; 22(1):1246. PubMed ID: 36241993
[TBL] [Abstract][Full Text] [Related]
16. Cervical cancer screening - The challenges of complete pathways of care in low-income countries: Focus on Malawi.
Cubie HA; Campbell C
Womens Health (Lond); 2020; 16():1745506520914804. PubMed ID: 32364058
[TBL] [Abstract][Full Text] [Related]
17. The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries.
Campos NG; Sharma M; Clark A; Lee K; Geng F; Regan C; Kim J; Resch S
Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():47-56. PubMed ID: 28691334
[TBL] [Abstract][Full Text] [Related]
18. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
19. Interventions targeted at women to encourage the uptake of cervical screening.
Staley H; Shiraz A; Shreeve N; Bryant A; Martin-Hirsch PP; Gajjar K
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD002834. PubMed ID: 34694000
[TBL] [Abstract][Full Text] [Related]
20. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.
Castanon A; Landy R; Pesola F; Windridge P; Sasieni P
Lancet Public Health; 2018 Jan; 3(1):e34-e43. PubMed ID: 29307386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
